about
Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors.Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma.Targeting Malignant Brain Tumors with Antibodies.Current therapeutic approaches to diffuse grade II and III gliomas.PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations.Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas.
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Targeting immune checkpoints in malignant glioma
@ast
Targeting immune checkpoints in malignant glioma
@en
Targeting immune checkpoints in malignant glioma
@nl
type
label
Targeting immune checkpoints in malignant glioma
@ast
Targeting immune checkpoints in malignant glioma
@en
Targeting immune checkpoints in malignant glioma
@nl
prefLabel
Targeting immune checkpoints in malignant glioma
@ast
Targeting immune checkpoints in malignant glioma
@en
Targeting immune checkpoints in malignant glioma
@nl
P2093
P2860
P921
P356
P1433
P1476
Targeting immune checkpoints in malignant glioma
@en
P2093
P2860
P356
10.18632/ONCOTARGET.12702
P407
P5008
P577
2016-10-16T00:00:00Z
2017-01-24T00:00:00Z